Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis
Obesity · 2023
DOI: 10.1002/oby.23752 ↗At a glance
Journal article in Obesity, 2023. Written by Joseph Azuri and 4 co-authors. Institution: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Major MEDLINE topics: Liraglutide, Diabetes Mellitus, Type 2. Cited 21 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Objective
Higher doses of the glucagon‐like peptide‐1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.
Methods
The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.
Results
Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%‐5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%‐13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032‐$3517) compared with $1845 (95% CI: $1707‐$1989) with semaglutide.
Conclusions
Semaglutide provides significantly better value for money than liraglutide for weight reduction.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Maccabi Healthcare Services, Tel Aviv, Israel.
- Clalit Health Services, Tel Aviv, Israel.
- Maximizing Health Outcomes Research Lab, Sapir College, Israel.
- Meuhedet Health Services, Jerusalem, Israel.
ORCID profiles: Joseph Azuri, Ariel Hammerman, Enis Aboalhasan
Cite
APA
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023). Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity. https://doi.org/10.1002/oby.23752
Vancouver
Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity. 2023. doi:10.1002/oby.23752
BibTeX
@article{Azuri2023,
author = {Azuri, Joseph and Hammerman, Ariel and Aboalhasan, Enis and Sluckis, Ben and Arbel, Ronen},
title = {Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis},
journal = {Obesity},
year = {2023},
doi = {10.1002/oby.23752}
}
EUVIMED